216 related articles for article (PubMed ID: 29489408)
1. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy.
Joo I; Lee JM; Lee ES; Ahn SJ; Lee DH; Kim SW; Ryu JK; Oh DY; Kim K; Lee KB; Jang JY
AJR Am J Roentgenol; 2018 May; 210(5):1059-1065. PubMed ID: 29489408
[TBL] [Abstract][Full Text] [Related]
2. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
[TBL] [Abstract][Full Text] [Related]
3. CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis.
Kim BR; Kim JH; Ahn SJ; Joo I; Choi SY; Park SJ; Han JK
Eur Radiol; 2019 Jan; 29(1):362-372. PubMed ID: 29931561
[TBL] [Abstract][Full Text] [Related]
4. Resectability of pancreatic adenocarcinoma in patients with locally advanced disease downstaged by preoperative therapy: a challenge for MDCT.
Morgan DE; Waggoner CN; Canon CL; Lockhart ME; Fineberg NS; Posey JA; Vickers SM
AJR Am J Roentgenol; 2010 Mar; 194(3):615-22. PubMed ID: 20173136
[TBL] [Abstract][Full Text] [Related]
5. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy.
Cassinotto C; Mouries A; Lafourcade JP; Terrebonne E; Belleannée G; Blanc JF; Lapuyade B; Vendrely V; Laurent C; Chiche L; Wagner T; Sa-Cunha A; Gaye D; Trillaud H; Laurent F; Montaudon M
Radiology; 2014 Oct; 273(1):108-16. PubMed ID: 24960211
[TBL] [Abstract][Full Text] [Related]
6. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
7. Preoperative CT Classification of the Resectability of Pancreatic Cancer: Interobserver Agreement.
Joo I; Lee JM; Lee ES; Son JY; Lee DH; Ahn SJ; Chang W; Lee SM; Kang HJ; Yang HK
Radiology; 2019 Nov; 293(2):343-349. PubMed ID: 31502935
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
Doppenberg D; van Dam JL; Han Y; Bonsing BA; Busch OR; Festen S; van der Harst E; de Hingh IH; Homs MYV; Kwon W; Lee M; Lips DJ; de Meijer VE; Molenaar IQ; Nuyttens JJ; Patijn GA; van Roessel S; van der Schelling GP; Suker M; Versteijne E; de Vos-Geelen J; Wilmink JW; van Eijck CHJ; van Tienhoven G; Jang JY; Besselink MG; Groot Koerkamp B;
Br J Surg; 2023 Sep; 110(10):1374-1380. PubMed ID: 37440421
[TBL] [Abstract][Full Text] [Related]
9. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
Akita H; Takahashi H; Ohigashi H; Tomokuni A; Kobayashi S; Sugimura K; Miyoshi N; Moon JH; Yasui M; Omori T; Miyata H; Ohue M; Fujiwara Y; Yano M; Ishikawa O; Sakon M
Eur J Surg Oncol; 2017 Jun; 43(6):1061-1067. PubMed ID: 28389044
[TBL] [Abstract][Full Text] [Related]
10. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
[TBL] [Abstract][Full Text] [Related]
11. Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy.
Tamm EP; Loyer EM; Faria S; Raut CP; Evans DB; Wolff RA; Crane CH; Dubrow RA; Charnsangavej C
Abdom Imaging; 2006; 31(5):568-74. PubMed ID: 16465578
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradiation therapy for pancreatic cancer.
Takahashi H; Yamada D; Asukai K; Wada H; Hasegawa S; Hara H; Shinno N; Ushigome H; Haraguchi N; Sugimura K; Yamamoto K; Nishimura J; Yasui M; Omori T; Miyata H; Ohue M; Yano M; Sakon M; Ishikawa O
Pancreatology; 2020 Jul; 20(5):919-928. PubMed ID: 32563596
[TBL] [Abstract][Full Text] [Related]
13. Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study.
Kim HY; Lee YJ; Chang W; Cho J; Park JH; Lee JC; Kim J; Hwang JH; Kim YH
Eur Radiol; 2022 Jun; 32(6):3799-3807. PubMed ID: 35032213
[TBL] [Abstract][Full Text] [Related]
14. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial.
Wittel UA; Lubgan D; Ghadimi M; Belyaev O; Uhl W; Bechstein WO; Grützmann R; Hohenberger WM; Schmid A; Jacobasch L; Croner RS; Reinacher-Schick A; Hopt UT; Pirkl A; Oettle H; Fietkau R; Golcher H
BMC Cancer; 2019 Oct; 19(1):979. PubMed ID: 31640628
[TBL] [Abstract][Full Text] [Related]
15. Preoperative evaluation of pancreatic cancer: comparison of gadolinium-enhanced dynamic MRI with MR cholangiopancreatography versus MDCT.
Park HS; Lee JM; Choi HK; Hong SH; Han JK; Choi BI
J Magn Reson Imaging; 2009 Sep; 30(3):586-95. PubMed ID: 19711405
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
[TBL] [Abstract][Full Text] [Related]
17. High-risk features in potentially resectable colon cancer: a prospective MDCT-pathology agreement study.
Santiago IA; Rodrigues ER; Germano AS; Costa AM; Manso RT; Gomes AP; Leichsenring CD; Geraldes VM
Abdom Radiol (NY); 2016 Oct; 41(10):1877-90. PubMed ID: 27315073
[TBL] [Abstract][Full Text] [Related]
18. Preoperative tumor restaging and resectability assessment of gastric cancers after chemotherapy: diagnostic accuracy of MDCT using new staging criteria.
Joo I; Kim SH; Ahn SJ; Lee ES; Shin CI; Lee HJ; Yang HK
Abdom Radiol (NY); 2017 Dec; 42(12):2807-2815. PubMed ID: 28643135
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment.
Cassinotto C; Cortade J; Belleannée G; Lapuyade B; Terrebonne E; Vendrely V; Laurent C; Sa-Cunha A
Eur J Radiol; 2013 Apr; 82(4):589-93. PubMed ID: 23287712
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.
Kharofa J; Tsai S; Kelly T; Wood C; George B; Ritch P; Wiebe L; Christians K; Evans DB; Erickson B
Radiother Oncol; 2014 Oct; 113(1):41-6. PubMed ID: 25443499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
